These 12‐month data confirm that in everyday clinical practice switching from low‐dose MDI to IDegLira in overtreated (well‐controlled or overcontrolled) patients with type 2 diabetes is safe, may induce weight loss, results in similar or better glycaemic control and substantially reduces insulin requirement on longer term. Here, INS is linked to type 2 diabetes mellitus.